Expert Review of Pharmacoeconomics and Outcomes Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Evaluation of Antimicrobial Stewardship Programs and antibiotic prescribing patterns among physicians in ambulatory care settings in Jordan
CONCLUSION: It was fair adoption of the core elements in the ambulatory care settings among Jordanian physicians. Progress necessitates a comprehensive strategy tailored to the needs of the health system.PMID:38064312 | DOI:10.1080/14737167.2023.2293197 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 8, 2023 Category: Health Management Authors: Mera A Ababneh Hana Abujuma Shoroq Altawalbeh Saddam Al Demour Source Type: research

The role of insurance policies in the drug pricing landscape
Expert Rev Pharmacoecon Outcomes Res. 2023 Dec 8:1-14. doi: 10.1080/14737167.2023.2292693. Online ahead of print.ABSTRACTINTRODUCTION: This overview paper aims at summarizing and analyzing the available literature on healthcare system organization and pricing policies of 11 European countries, comparing them to the Bulgarian pharmaceutical system. The countries were selected based on the reference basket for the pricing of pharmaceuticals in Bulgaria - Belgium, Greece, Spain, Italy, Latvia, Lithuania, Romania, Slovakia, Slovenia, and France.AREAS COVERED: In the first part, we explore the health system models in the above-...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 8, 2023 Category: Health Management Authors: Alexandra Savova Manoela Manova Konstantin Tachkov Guenka Petrova Source Type: research

Evaluation of Antimicrobial stewardship Programs and antibiotic prescribing patterns among physicians in ambulatory care settings in Jordan
CONCLUSION: It was fair adoption of the core elements in the ambulatory care settings among Jordanian physicians. Progress necessitates a comprehensive strategy tailored to the needs of the health system.PMID:38064312 | DOI:10.1080/14737167.2023.2293197 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 8, 2023 Category: Health Management Authors: Mera A Ababneh Hana Abujuma Shoroq Altawalbeh Saddam H Aldemour Source Type: research

Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial
CONCLUSION: Trastuzumab deruxtecan was not a cost-effective treatment option for patients with HER2-positive metastatic breast cancer in China. However, the use of trastuzumab deruxtecan may offer a cost-effective treatment alternative provided that its price is diminished.PMID:38039117 | DOI:10.1080/14737167.2023.2291157 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 1, 2023 Category: Health Management Authors: Zhiwei Zheng Hongcai Chen Hongfu Cai Siqi Xu Source Type: research

First-line tislelizumab for advanced or metastatic esophageal squamous cell carcinoma:A cost-effectiveness analysis
CONCLUSION: Tislelizumab plus chemotherapy as first-line treatment for advanced or metastatic ESCC is may be a cost-effective option compared to chemotherapy alone.PMID:38031985 | DOI:10.1080/14737167.2023.2290609 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 30, 2023 Category: Health Management Authors: Zhiwei Zheng Hongcai Chen Hongfu Cai Huide Zhu Source Type: research